Special Issue

Strategies and Innovations to Recover Post-Pandemic Losses in Routine Immunization Coverage

Message from the Guest Editor

The COVID-19 pandemic disrupted routine immunization programs worldwide, leading to declines in vaccination coverage and an increased vulnerability to vaccine-preventable diseases. Post-pandemic efforts to improve coverage have progressed; however, we are still significantly below pre-pandemic vaccination levels. This Special Issue focuses on strategies and collaborative efforts to enhance routine immunization coverage. Our goal is to provide countries and stakeholders with evidence-based practices and lessons learned to prevent outbreaks of vaccine-preventable diseases and to meet immunization goals. We welcome original research articles and reviews for this Special Issue. Research areas may include (but are not limited to) the following:

- Innovative approaches to catch-up vaccination;
- Community engagement and communication strategies to increase vaccine demand and uptake;
- Policy and funding mechanisms to support immunization recovery;
- Technological innovations in vaccine delivery and monitoring.

Thank you for your continued commitment to improving immunization coverage. We look forward to receiving your contributions.

Guest Editor

Dr. Noha H. Farag

- 1. U.S. Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
- 2. U.S. Centers for Disease Control and Prevention, Middle East and North Africa Regional Office. Muscat. Oman

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/247967

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

